Neuropathy, Diabetic — Fluid Retention in Rosiglitazone Treated Subjects With Autonomic Neuropathy.
Citation(s)
A 16-week, Randomised, Double-blind, Placebo-controlled, Single-centre Study to Investigate Fluid Retention in Insulin-treated Subjects With Type 2 Diabetes Mellitus and Varying Degrees of Autonomic Neuropathy When Administered Rosiglitazone 4mg Twice Daily